Pharmacogenomic Evaluation of Drug-Induced Transporter Expression Changes in Human Cell Models

Abstract

Drug transporters are major determinants of absorption, distribution, hepatic and renal elimination, tissue exposure, and pharmacological response. Their expression can be altered by xenobiotics through nuclear receptor activation, inflammatory signaling, epigenetic regulation, post-transcriptional mechanisms, and transporter protein trafficking. These changes may produce clinically important drug–drug interactions that are not adequately predicted by static genotyping alone. Pharmacogenomic evaluation in human cell models provides a mechanistic framework for integrating inherited variation with drug-induced changes in transporter abundance and function. Relevant systems include primary human hepatocytes, intestinal epithelial models, renal proximal tubule cells, blood–brain barrier models, induced pluripotent stem cell-derived cells, and three-dimensional organoid or organ-on-chip platforms. This review summarizes the biological basis, experimental methods, clinical relevance, risk factors, diagnostic approaches, therapeutic implications, emerging technologies, and guideline considerations associated with pharmacogenomic assessment of drug-induced transporter expression changes. Particular emphasis is placed on the interpretation of genotype-by-drug interactions, the need to distinguish messenger RNA induction from functional transporter activity, and the translation of in vitro findings into individualized prescribing strategies.

Introduction

Membrane transporters regulate the movement of endogenous compounds and medicines across cellular barriers. Solute carrier and ATP-binding cassette transporter families are especially important in the intestine, liver, kidney, placenta, blood–brain barrier, and tumor tissues. Transporters such as P-glycoprotein, breast cancer resistance protein, organic anion transporting polypeptides, organic anion transporters, organic cation transporters, multidrug and toxin extrusion proteins, and bile salt export pumps influence systemic exposure and intracellular drug concentrations. Genetic polymorphisms in the genes encoding these proteins can modify baseline expression, substrate recognition, cellular localization, and transport capacity.

Pharmacogenomics traditionally focuses on inherited sequence variation, whereas drug-induced transporter regulation represents a dynamic component of pharmacology. A medicine may activate pregnane X receptor, constitutive androstane receptor, aryl hydrocarbon receptor, or other transcriptional pathways, resulting in altered transporter expression. Conversely, cytokines, oxidative stress, cholestasis, and tissue injury may suppress transporter activity despite unchanged genotype. Consequently, the clinically relevant phenotype is often determined by the interaction of genetic background, concomitant medication, disease state, exposure duration, and cellular context. Human cell models are valuable because they permit controlled assessment of these interacting factors before clinical investigation.

Epidemiology / Disease Burden

Drug transporter-mediated interactions contribute to a substantial proportion of preventable medication-related harm, although their exact population frequency is difficult to quantify. The burden is greatest among patients receiving polypharmacy, narrow-therapeutic-index medicines, or treatment for conditions requiring long-term exposure. Transplant recipients, individuals with cancer, patients with human immunodeficiency virus infection, older adults, and people with cardiovascular or neurological disease frequently receive combinations capable of modifying transporter activity. In these settings, altered transporter expression can lead to treatment failure, toxicity, hospitalization, or the need for additional monitoring.

The clinical impact is not limited to overt toxicity. Reduced intestinal efflux may increase oral bioavailability, while induced hepatic uptake or renal secretion may lower plasma concentrations. In contrast, suppression of hepatic or renal transport can increase exposure to active compounds or metabolites. Population differences in transporter alleles may change the magnitude of these effects, but environmental influences often account for substantial variability. Human cell-based pharmacogenomic studies therefore address an important translational gap between single-gene association studies and complex real-world medication responses.

Pathophysiology

Drug-induced transporter expression changes arise through several interconnected mechanisms. Ligand-activated nuclear receptors can bind regulatory elements within transporter genes and coordinate transcription with drug-metabolizing enzymes. For example, activation of pregnane X receptor may increase expression of intestinal and hepatic efflux pathways, whereas inflammatory signaling through nuclear factor kappa B and related mediators can repress transporter transcription. MicroRNAs may alter messenger RNA stability or translation, and epigenetic modifications can produce persistent changes in chromatin accessibility. Drugs may also modify transporter trafficking, membrane insertion, phosphorylation, ubiquitination, or degradation without substantially changing transcript abundance.

Genetic variation can modify each stage of this response. A promoter variant may alter inducibility, a coding variant may affect transporter stability or substrate specificity, and a regulatory variant may change receptor binding. The result is a genotype-by-environment interaction in which two patients exposed to the same inducer or inhibitor develop different functional phenotypes. Importantly, increased messenger RNA does not necessarily indicate increased transport. Protein maturation, membrane localization, cellular polarity, competing substrates, and intracellular energy availability must be evaluated before assigning clinical meaning.

Risk Factors

Risk factors for clinically significant transporter dysregulation include polypharmacy, repeated exposure to known enzyme or transporter modulators, impaired hepatic or renal function, systemic inflammation, sepsis, cholestatic disease, malignancy, malnutrition, and advanced age. Genetic susceptibility may be particularly relevant when a variant reduces baseline transporter reserve or changes regulatory responsiveness. Patients with organ transplantation and oncology patients may experience simultaneous exposure to immunosuppressants, antimicrobials, antineoplastic agents, and supportive treatments, creating a complex interaction network.

Experimental risk factors also influence interpretation. Cell passage number, donor genotype, culture medium, extracellular matrix composition, differentiation state, oxygen tension, and exposure duration can all affect transporter expression. Primary hepatocytes may lose differentiated function during prolonged culture, while immortalized cell lines may not reproduce normal tissue polarity. Failure to control these variables can lead to false-positive induction or conceal clinically relevant effects. Robust studies should therefore include multiple donors, appropriate positive and negative controls, concentration ranges linked to clinical exposure, and independent confirmation at transcript, protein, and functional levels.

Clinical Features

Drug-induced transporter changes do not produce a unique symptom pattern. Clinical manifestations reflect the affected medicine and organ system. Increased exposure may present as bleeding, central nervous system depression, nephrotoxicity, hepatotoxicity, QT prolongation, myopathy, hypoglycemia, or other concentration-dependent adverse effects. Reduced exposure may manifest as virologic breakthrough, transplant rejection, seizures, uncontrolled hypertension, cancer progression, or recurrence of inflammatory disease. Altered central nervous system transport can influence sedation, analgesic response, neurotoxicity, or treatment failure even when plasma concentrations appear acceptable.

The timing of symptoms is informative. Transcriptional induction often develops over days and may persist after discontinuation because transporter turnover and regulatory signaling require time to normalize. Functional inhibition can occur rapidly, sometimes after a single dose. Clinicians should therefore assess the temporal relationship between treatment initiation, dose changes, new co-medications, inflammatory episodes, and clinical response rather than attributing all variability to nonadherence or disease progression.

Diagnosis

Evaluation begins with a complete medication and supplement history, assessment of organ function, review of treatment response, and identification of concentration-dependent toxicity. Therapeutic drug monitoring is useful for selected substrates, but measured plasma concentration may not reflect intracellular exposure or tissue-specific transport. Pharmacogenomic testing can identify variants with established relevance, although the absence of a recognized variant does not exclude inducibility or suppression caused by concomitant drugs or disease.

Research and specialized clinical evaluation may include transporter genotyping, transcriptomic profiling, quantitative proteomics, and functional assays using patient-derived cells. Reporter assays can investigate receptor activation, while uptake and efflux experiments determine whether expression changes translate into altered transport. In vitro-in vivo extrapolation should incorporate clinically relevant free concentrations, protein binding, transporter abundance, organ scaling, and disease-specific physiology. A clinically useful interpretation requires convergence of genetic, molecular, functional, pharmacokinetic, and clinical data rather than reliance on a single biomarker.

Treatment & Management

Management is primarily mechanism based. When a clinically important interaction is suspected, prescribers should consider discontinuing the perpetrator drug, selecting a noninteracting alternative, adjusting the victim-drug dose, or increasing therapeutic drug monitoring. Dose modification should account for the direction and duration of the transporter change, renal and hepatic function, therapeutic index, and availability of validated pharmacokinetic targets. Abrupt replacement of essential treatment may be unsafe, so decisions should balance interaction risk against disease control.

Patients should receive counseling about nonprescription medicines, herbal products, and dietary constituents that may regulate transport pathways. Interprofessional review by pharmacists, physicians, laboratory specialists, and pharmacogenomics experts can improve interpretation in complex cases. In research settings, drug-induced expression data should be connected to clinical endpoints and not treated as a surrogate for outcome without validation. Serial sampling may be necessary because transporter regulation is dynamic and may change during treatment, recovery from inflammation, or withdrawal of an inducer.

Recent Advances / Emerging Therapies

Recent advances include patient-derived induced pluripotent stem cell models, intestinal and hepatic organoids, microphysiological systems, and organ-on-chip platforms that recreate tissue architecture, flow, polarity, and multicellular signaling. These systems can be generated from donors with defined transporter genotypes, enabling direct comparison of inherited and acquired regulatory effects. Single-cell transcriptomics and spatial molecular profiling further distinguish cell-type-specific responses that are obscured in bulk tissue measurements.

Artificial intelligence and systems pharmacology are increasingly used to integrate genomic, transcriptomic, proteomic, and pharmacokinetic datasets. Their value depends on transparent model development, external validation, biologically interpretable features, and careful management of population bias. CRISPR-based editing permits creation of isogenic cell pairs differing at a single transporter locus, helping determine whether a variant alters inducibility or merely changes baseline expression. Future therapeutic strategies may include selective modulation of transporter regulatory pathways, targeted drug delivery that bypasses variable transport, and adaptive dosing algorithms that combine genotype with real-time pharmacokinetic measurements.

Guideline Recommendations

Current pharmacogenomic guidance generally supports clinical testing when a genotype has a validated association with drug exposure, efficacy, or toxicity and when an actionable prescribing recommendation exists. Transporter findings should be interpreted alongside established recommendations for drug-metabolizing enzymes, organ function, and therapeutic drug monitoring. In the absence of a validated clinical guideline, an in vitro transporter induction result should not independently mandate a dose change. Instead, it should prompt assessment of alternative therapies, interaction resources, pharmacokinetic monitoring, and patient-specific risk.

For clinical research and model qualification, studies should follow principles of good laboratory practice, use human-relevant exposure conditions, report donor characteristics and genetic background, and measure both expression and transport function. Investigators should distinguish induction from inhibition, evaluate reversibility, and document the relationship between in vitro concentrations and unbound clinical concentrations. Regulatory and scientific consensus increasingly favors integrated evidence that combines mechanistic transporter data with clinical pharmacokinetics and outcomes. Standardized protocols and interoperable databases will be essential for translating findings across laboratories and populations.

Conclusion

Pharmacogenomic evaluation of drug-induced transporter expression changes provides a framework for understanding why patients with similar prescriptions may experience different exposure, efficacy, and toxicity. Human cell models can reveal interactions between inherited variation, receptor-mediated regulation, inflammation, and tissue-specific transporter biology, but their findings must be validated through protein-level and functional assays and linked to clinical pharmacokinetics. The most reliable approach combines genotype, medication history, disease state, organ function, therapeutic drug monitoring, and mechanistic model evidence. As organoids, isogenic cell systems, single-cell technologies, and computational pharmacology mature, dynamic transporter phenotyping may become an important component of precision prescribing and safer medication development.